Loading…
← CockpitCompetitor Analysis › EGTX.ST Egetis Therapeutics ABOpen in the cockpit ↗

Egetis Therapeutics ABEGTX.STCompetitor analysis, valuation and peers

Sweden · SEK·Health Care›Pharmaceuticals: Major
Momentum leader 99
Mkt cap
$509M
US dollars, full cap
Free float
40%
of shares outstanding
$/day
$4.69M
20-day average traded
Fwd P/E
15.1×
forward earnings
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · SEKSEK 11.14
1D+0.2%
1W+0.2%
1M+21.5%
3M+52.0%
6M+76.0%
YTD+108.6%
1Y+73.5%
ATR %2.6%
52w lowhigh0.5% off high

What Egetis Therapeutics does

Employees: 42

Egetis Therapeutics at a glance

Size Egetis Therapeutics (EGTX.ST) is a Sweden Health Care company (Pharmaceuticals: Major) with a market value of $509M, the 172nd largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 11.14 on 18 Nov 2026.

Performance Over six months the shares gained 76.0%, against -20.4% for the median peer and +2.8% for the Sweden market (cap-weighted) — 3rd highest of 19 in its peer set.

Growth Revenue grew 26.7% over the last twelve months (peer median +7.6%); the operating margin is -644.9% (peer median 11.4%).

Valuation It trades at 15.1× forward earnings against a peer median of 14.3× (3rd cheapest of 5).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026EGTX.ST 183Peer median 81
Six months, rebased to 100: Egetis Therapeutics against the median of its 20 peers (local-currency closes).

Egetis Therapeutics financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueSEK 70.2MSEK 62.4MSEK 46.1MSEK 57.6MSEK 22.6M
Revenue growth—+35%-20%+155%—
Gross profitSEK 19.5MSEK 12.4MSEK 34.5M-SEK 127M-SEK 60.7M
EBITDAn/a-SEK 343M-SEK 324M-SEK 317M-SEK 194M
Net income-SEK 470M-SEK 342M-SEK 344M-SEK 327M-SEK 194M
Free cash flow-SEK 353M-SEK 268M-SEK 228M-SEK 278M-SEK 174M
Capital expenditureSEK 1.00MSEK 1.50MSEK 0SEK 0SEK 0
Total debtSEK 73.9MSEK 85.0MSEK 117MSEK 113MSEK 2.70M

Quarterly statements and history in the cockpit →

Egetis Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%603676INDPGUJTHEM603207GYRE600222TKNO600513003090AARTIDRUGS1666SUPRIYA301277EGTX.ST6-month return →1-month return →
Up and to the right = strong over both horizons. Egetis Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%10×20×30×003090AARTIDRUGS1666SUPRIYAEGTX.STRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Egetis Therapeutics is the large dot.

Egetis Therapeutics competitors and peer comparison

How Egetis Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Egetis Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureEGTX.STPeer medianRank in peer set
1-month return+21.5%-7.0%2nd highest of 20
6-month return+76.0%-20.4%3rd highest of 19
Distance from 52-week high-0.5%-40.7%highest of 20
Revenue growth (TTM)+26.7%+7.6%2nd highest of 19
Operating margin-644.9%11.4%lowest of 19
Forward P/E15.1×14.3×3rd cheapest of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Egetis Therapeutics EGTX.STSweden$509M+76%+27%-645%15.1×n/an/a
Xizang Weixinkang Pharmaceutical 603676.SSChina$513M-22%-8%16%n/a-6.1%+9.6%
Indaptus Therapeutics INDPUnited States$505M+147%n/an/an/an/an/a
Gujarat Themis Biosyn GUJTHEM.NSIndia$505M+2%+18%39%n/an/an/a
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%n/a-5.4%+7.6%
Beijing Science Sun Pharmaceutical 300485.SZChina$517M-29%-11%-8%n/an/an/a
Gyre Therapeutics GYREUnited States$500M-28%+14%-18%n/an/an/a
Henan Taloph Pharmaceutical Stock 600222.SSChina$497M-21%-5%7%n/a16.7%+4.4%
Alpha Teknova TKNOUnited States$496M+113%+15%-32%n/an/an/a
Jiangsu Lianhuan Pharmaceutical 600513.SSChina$496M-41%+14%0%n/an/an/a
Daewoong 003090.KSSouth Korea$495M-28%+6%11%4.1×n/an/a
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%21.3×22.1%+3.5%
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%n/a5.9%-4.1%
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%7.3×-17.2%+6.3%
Evonile Pharma EVONILE.NSIndia$529Mn/a-5%12%n/a49.3%-1.5%
Supriya Lifescience SUPRIYA.NSIndia$529M-15%+23%26%36.2×28.2%+15.8%
Jinling Pharmaceutical 000919.SZChina$529M-15%-8%1%n/a2.4%+5.0%
Electra Therapeutics ETRAUnited States$530Mn/an/an/an/an/an/a
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%n/a8.9%+9.1%
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%n/a3.3%-1.1%
Chimin Health Management 603222.SSChina$533M-31%+1%-28%n/an/an/a

Questions

Which companies are Egetis Therapeutics's closest peers?
The cockpit's peer set: Xizang Weixinkang Pharmaceutical (603676.SS), Indaptus Therapeutics (INDP), Gujarat Themis Biosyn (GUJTHEM.NS), Shanghai Xiao Fang Pharmaceutical (603207.SS), Beijing Science Sun Pharmaceutical (300485.SZ), Gyre Therapeutics (GYRE), Henan Taloph Pharmaceutical Stock (600222.SS), Alpha Teknova (TKNO).
Is Egetis Therapeutics expensive compared with its peers?
On forward p/e it trades at 15.1× against a peer median of 14.3×, 3rd cheapest of 5 in its peer set.
How has Egetis Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +76.0% against -20.4% for the median peer; over one year +73.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.